In vivo最新文献_第10页

Ball Tip Feeler vs. Depth Gauge: Detection of Bony Pedicle Defects Before Pedicle Screw Insertion. 球头探测仪与深度计：在椎弓根螺钉插入前检测骨椎弓根缺陷。

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13876

Ulf Brunnemer, Sabine Roth, Christian W Müller, Tobias Hüfner, Sebastian Decker

{"title":"Ball Tip Feeler vs. Depth Gauge: Detection of Bony Pedicle Defects Before Pedicle Screw Insertion.","authors":"Ulf Brunnemer, Sabine Roth, Christian W Müller, Tobias Hüfner, Sebastian Decker","doi":"10.21873/invivo.13876","DOIUrl":"10.21873/invivo.13876","url":null,"abstract":"Background/aim: The objective of this study was to investigate whether the detection rates of pedicle breaches depended on the surgeon's experience level and whether different instruments resulted in varied palpation quality.Materials and methods: Experienced surgeons (ES) (n=8) and inexperienced surgeons (IS) (n=10) were compared. The study was performed using a sawbone model of the spine. Pedicle defects were created at various positions and levels. Participants detected and located the bony defects using a depth gauge and a straight ball tip feeler. After the first measurement, the IS group underwent training focused on identifying bone defects. The experiment was repeated after three weeks under identical conditions.Results: A significant difference was found between ES and IS in the time required to palpate pedicles and bony defects using the ball tip feeler during the first measurement (297.2±114.4 s vs. 202.1±77.9 s; p=0.05). However, after training and during the second measurement three weeks later, these differences were no longer observed (223.7±65.1 s vs. 212.2±73.6 s; p=0.73). Notably, no significant differences were found in the accuracy in detecting bony pedicle defects between the two groups, regardless of the device used. Furthermore, no improvement was found in the IS group after training, regardless of the device used.Conclusion: ES and IS accurately detected pedicle breaches without significant differences. Training did not affect detection rates between the groups, and the choice of device did not affect the accuracy of pedicle breach detection.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"724-731"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Boron-dipyrromethene Staining May Enhance Fat Detection in the MASLD Zebrafish Model: NGS-validated lncRNA Profiling. 硼-二吡咯烷染色可增强MASLD斑马鱼模型中的脂肪检测：ngs验证的lncRNA分析。

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13879

Wookjae Jung, Min Hye Kim, Jung Wook Yang, Dong Chul Kim, Jong Sil Lee, Jeong-Hee Lee, Hyo Jung An, Dae Hyun Song

{"title":"Boron-dipyrromethene Staining May Enhance Fat Detection in the MASLD Zebrafish Model: NGS-validated lncRNA Profiling.","authors":"Wookjae Jung, Min Hye Kim, Jung Wook Yang, Dong Chul Kim, Jong Sil Lee, Jeong-Hee Lee, Hyo Jung An, Dae Hyun Song","doi":"10.21873/invivo.13879","DOIUrl":"10.21873/invivo.13879","url":null,"abstract":"Background/aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a serious global public health concern. Long non-coding RNAs (lncRNAs) have been identified as key contributors to MASLD pathogenesis. Zebrafish can be utilized to study the relationship between MASLD and lncRNAs because of their similarity to human genes. Oil Red O staining is a traditional method for confirming liver fatty changes; however, it has several limitations. This study aimed to evaluate the efficacy of boron-dipyrromethene (BODIPY) in detecting fatty changes in the liver.Materials and methods: Liver tissues were collected from 30 zebrafish that were fed a BODIPY-containing high-cholesterol diet. Oil Red O and BODIPY staining were evaluated by two pathologists, and next-generation sequencing (NGS) was performed using liver tissues categorized into high fatty change (six liver tissues) and low fatty change (six liver tissues) groups.Results: BODIPY and Oil Red O staining of zebrafish liver sections correlated significantly (p=0.009). NGS identified eight differentially expressed lncRNAs with over a 10-fold difference between the high- and low-fatty acid change groups. Of these, three showed lncRNA-mRNA interaction networks linked to human disorders.Conclusion: BODIPY staining is a reliable alternative to Oil Red O staining for assessing fatty changes in MASLD zebrafish models, particularly when examining frozen liver sections.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"749-757"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Short- and Long-term Surgical Results of Extended Surgery for Widespread Gallbladder Carcinoma. 扩大手术治疗广泛性胆囊癌的短期和长期疗效分析。

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13907

Takehiro Noji, Shintaro Takeuchi, Masataka Wada, Kimitaka Tanaka, Aya Matsui, Yoshitsugu Nakanishi, Toshimichi Asano, Toru Nakamura, Yasuyuki Kawamoto, Satoshi Hirano

{"title":"Short- and Long-term Surgical Results of Extended Surgery for Widespread Gallbladder Carcinoma.","authors":"Takehiro Noji, Shintaro Takeuchi, Masataka Wada, Kimitaka Tanaka, Aya Matsui, Yoshitsugu Nakanishi, Toshimichi Asano, Toru Nakamura, Yasuyuki Kawamoto, Satoshi Hirano","doi":"10.21873/invivo.13907","DOIUrl":"10.21873/invivo.13907","url":null,"abstract":"Background/aim: Hepatectomy with extrahepatic bile duct resection (Hx+EBDR), pancreaticoduodenectomy (PD), and occasionally hepatopancreaticoduodenectomy (HPD) are required for the treatment of advanced gallbladder cancer (GBC). This study aimed to clarify the clinical value of these extended surgeries for GBC.Patients and methods: We retrospectively reviewed the medical records of patients who underwent curative resection (Surg-G, n=59), and their survival rates were compared with those of patients with unresectable GBC who underwent chemotherapy (CTx-G, n=63).Results: We performed PD (n=15), Hx+EBDR (n=37), and HPD (n=7). The postoperative complication and death rates were as follows: PD, 40% and 7%, respectively; Hx+EBDR, 89% and 14%, respectively; and HPD, 57% and 0%, respectively. Concomitant vascular resection (VR) was required in 61% of the patients. The 5-year overall survival rate and median survival time (MST) for Surg-G were 25.1% and 26 months, respectively, whereas those for CTx-G were 4.6% and 14.4 months, respectively. There were no significant differences between the surgical procedures. Patients who underwent VR had similar prognoses (5-year overall survival rate and MST: 14.5% and 22.3 months, respectively) as the patients in CTx-G.Conclusion: Although extended surgery may be considered for patients with GBC, careful patient selection and new therapeutic strategies are required, especially for those requiring VR.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1022-1032"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Short-term Efficacy of Botulinum Toxin A for Refractory Overactive Bladder in Female Patients. A型肉毒毒素治疗女性难治性膀胱过动症的近期疗效观察。

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13899

Hirotaka Sato, Takahiro Watanabe, Shota Otsuka, Sachiyuki Tsukada

{"title":"Short-term Efficacy of Botulinum Toxin A for Refractory Overactive Bladder in Female Patients.","authors":"Hirotaka Sato, Takahiro Watanabe, Shota Otsuka, Sachiyuki Tsukada","doi":"10.21873/invivo.13899","DOIUrl":"10.21873/invivo.13899","url":null,"abstract":"Background/aim: This study aimed to assess the effectiveness and safety of 100 U onabotulinumtoxinA (also known as botulinum toxin type A) for overactive bladder (OAB) and urgency urinary incontinence (UUI) in Japanese women.Patients and methods: This prospective, nonrandomized study was conducted as a single-center clinical trial in Japan and targeted patients with OAB that did not respond adequately to standard treatments, including anticholinergics and β3-adrenergic receptor agonists. A total of 26 patients received a single intradetrusor injection of onabotulinumtoxinA. The primary endpoint was the change in the number of daily UUI episodes between baseline and week 12. The secondary endpoints were improvements in other OAB symptoms and health-related quality of life (HRQoL). Adverse events were monitored.Results: Patients who received onabotulinumtoxinA experienced a significant reduction in the mean number of daily UUI episodes between baseline and week 12 (-3.49; p<0.001). Significant improvements in all secondary endpoints except the personal relationships domain of King's Health Questionnaire were observed. Adverse events, such as urinary tract infection, cystitis, dysuria, and increased postvoid residual urine volume, occurred more frequently with onabotulinumtoxinA. However, the severity of most adverse events was mild or moderate.Conclusion: OnabotulinumtoxinA administered at a dose of 100 U was well-tolerated and resulted in significant and clinically meaningful improvements in the OAB symptoms and HRQoL of patients whose OAB could not be adequately managed with other treatments.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"942-950"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Participant Perspectives on Pulse-Echo Ultrasound Technology vs. Dual Energy X-Ray Absorptiometry (DXA): A Comparative Study. 参与者对脉冲回波超声技术与双能x射线吸收仪（DXA）的看法：比较研究。

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13895

Abdulkareem Algahtani, Mohammed Asiri, Kinan Mokbel, Robert Meertens, Jon Fulford, William David Strain, Karen Knapp

{"title":"Participant Perspectives on Pulse-Echo Ultrasound Technology vs. Dual Energy X-Ray Absorptiometry (DXA): A Comparative Study.","authors":"Abdulkareem Algahtani, Mohammed Asiri, Kinan Mokbel, Robert Meertens, Jon Fulford, William David Strain, Karen Knapp","doi":"10.21873/invivo.13895","DOIUrl":"10.21873/invivo.13895","url":null,"abstract":"Background/aim: Osteoporosis is a global health concern causing severe fractures, and timely diagnosis with thorough bone assessment is crucial for effective management. Diagnostic tools such as Bindex® (a novel ultrasound-based diagnostic technology) and DXA (X-ray-based) play a key role in identifying and assessing bone conditions. This study aimed to evaluate and compare these two approaches' overall acceptability, comfort, and preference. Feelings of pain and perceptions regarding the scan length during the Bindex® scanning procedure were also assessed.Patients and methods: Two diagnostic imaging tools were used in this comparative study: Bindex® (pulse-echo ultrasound technology) and DXA (X-ray technology). A bespoke questionnaire was employed to gather the participants' responses, which were coded numerically, and data were analysed statistically.Results: Despite minor discomfort associated with the gel application, Bindex® received significantly higher acceptability and comfort ratings than DXA, with many participants preferring its non-ionising radiation. Both methods were generally well-received, though some favoured DXA for not requiring gel.Conclusion: In addition to enhancing diagnostic workflows, we demonstrated that Bindex® scans can improve patient satisfaction. This study emphasised the importance of innovating medical imaging diagnostic tools to prioritise patient acceptability and comfort.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"909-916"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could Transcervical Radiofrequency Ablation Become a Therapy Option for Focal Adenomyosis? 经宫颈射频消融能成为局灶性脑卒中的治疗选择吗？

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13901

Elvin Piriyev, Angelika Dieter, Sven Schiermeier, Stefan Renner, Thomas Römer

{"title":"Could Transcervical Radiofrequency Ablation Become a Therapy Option for Focal Adenomyosis?","authors":"Elvin Piriyev, Angelika Dieter, Sven Schiermeier, Stefan Renner, Thomas Römer","doi":"10.21873/invivo.13901","DOIUrl":"10.21873/invivo.13901","url":null,"abstract":"Background/aim: Adenomyosis is a common gynecological disease characterized by the presence of ectopic endometrial tissue (endometrial stroma and glands) within the myometrium. It is classified into two main types: diffuse and focal. The aim of this study was to present the outcomes of patients with focal adenomyosis following treatment with transcervical radiofrequency ablation.Patients and methods: This was a retrospective analysis of patients treated with the Sonata® System. A total of 574 cases were analyzed, all performed at two centers in Germany: Academic Hospital Cologne Weyertal and Hospital Böblingen.Results: Thirty patients with focal adenomyosis were treated with transcervical radiofrequency ablation. All surgeries were performed without any complications. The mean surgery's time was 30.7 minutes, while the mean ablation time was 8.5 minutes. At the time of this report, 27 patients had returned for follow-up. 89% of patients reported improvement in their symptoms. No patient reported a worsening of their symptoms. The procedure reduced the average focal lesion size from 4.4 cm to 2.8 cm. No postoperative complications were observed. All patients reported satisfaction with the procedure.Conclusion: Transcervical radiofrequency ablation appears to be an effective approach for treating adenomyosis. The Sonata® System, in particular, offers notable advantages, making it a potentially valuable alternative to conventional procedures like hysterectomy and tissue excision. This minimally invasive approach preserves the uterus, providing a less invasive and more patient-centered treatment option for adenomyosis.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"961-968"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of Risedronate Analog on Extraction Socket Healing in Mice. 利塞膦酸类似物对小鼠拔牙槽愈合的影响。

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13870

Moeka Kasagawa, Yuichi Mine, Mizuho Sano, Yukinaga Kurokui, Ayano Ueda, Masato Kaku, Hiroki Nikawa, Takeshi Murayama

{"title":"Analysis of Risedronate Analog on Extraction Socket Healing in Mice.","authors":"Moeka Kasagawa, Yuichi Mine, Mizuho Sano, Yukinaga Kurokui, Ayano Ueda, Masato Kaku, Hiroki Nikawa, Takeshi Murayama","doi":"10.21873/invivo.13870","DOIUrl":"10.21873/invivo.13870","url":null,"abstract":"Background/aim: Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse effect associated with anti-resorptive medications like nitrogen-containing bisphosphonates (N-BPs), particularly zoledronate (ZOL). This study aimed to investigate whether a BP analog with high bone affinity but minimal anti-resorptive activity, NE-58051, could induce MRONJ-like lesions in a mouse model.Materials and methods: Female C57BL/6J mice (n=6 per group) were administered ZOL (250 μg/kg intravenously, twice weekly) for one or two weeks, or NE-58051 (250 μg/kg intravenously, twice weekly) for two weeks. Two weeks after initiation of study, the bilateral first molars were extracted. Mice were euthanized after a total duration of four weeks. Histological assessments evaluated necrotic bone area and osteoclast activity at extraction sites. Serum tartrate-resistant acid phosphatase isoform 5b (TRAcP-5b) levels were measured.Results: Mice treated with ZOL for two weeks exhibited significant increases in empty osteocytic lacunae and necrotic bone area compared to the saline group, indicating the development of MRONJ-like lesions. NE-58051-treated mice did not show significant differences in necrotic bone area or osteoclast activity compared to controls. No significant differences were observed in serum TRAcP-5b levels among all groups.Conclusion: High bone affinity without potent inhibition of bone resorption does not induce MRONJ-like lesions in mice. These findings suggest that the potent anti-resorptive activity of N-BPs is a key factor in MRONJ development, highlighting the importance of bone turnover suppression in the pathogenesis of this condition.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"648-655"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prolonged Viral Shedding of SARS-CoV-2 in Patients With Underlying Haemato-oncological Disease. 潜在血液肿瘤疾病患者中SARS-CoV-2的长期病毒脱落

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13887

Alexander Casimir Angleitner, Lena Levien, Judith Büntzel

{"title":"Prolonged Viral Shedding of SARS-CoV-2 in Patients With Underlying Haemato-oncological Disease.","authors":"Alexander Casimir Angleitner, Lena Levien, Judith Büntzel","doi":"10.21873/invivo.13887","DOIUrl":"10.21873/invivo.13887","url":null,"abstract":"Background/aim: Case reports describe prolonged COVID19 shedding in patients with malignant hematological disease. Similarly, we observed extended viral shedding in hemato-oncological patients (HP) at our SARS-CoV-2 unit. This raises the question of whether HP are more susceptible to prolonged SARS-CoV-2 shedding and which aspects of immunosuppression contribute to this phenomenon.Patients and methods: Data from HP treated at a single center between 02/2022 and 02/2023 were retrospectively analyzed. Overall, 47 HP with a positive SARS-CoV-2 PCR test were included. Additional data on 16 HP were retrieved from literature. The duration of SARS-CoV-2 positivity (t[SARS+]) was compared between subgroups with different diagnoses, immune status, and HP with and without medical treatment of SARS-CoV-2.Results: t[SARS+] of HP was 47 days [interquartile range (IR)=25-95] and 12 HP (19%) were still positive by the end of the follow-up. In our cohort, four HP died while still shedding SARS-CoV-2 [t[SARS+]=47 days (IR=33.5-86)]. Different oncological diagnoses did not influence t[SARS+]. HP under steroids had a significantly longer average t[SARS+] (108 days vs. 45 days; p=0.016). HP with B cell depletion/T cell depletion and leukopenia were found to require more time to test negative for SARS-CoV-2 (p Logrank <0.05). Vaccinated HP had a significantly shorter duration of viral shedding (vaccinated 35.5 days vs. not vaccinated 86 days; p Logrank <0.01).Conclusion: Prolonged viral shedding is a common occurrence in HP. Our data illustrate that HP under immune suppression show a significantly longer t[SARS+]. Furthermore, we demonstrate that vaccination influences the length of viral shedding.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"844-850"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma. 营养指数对不能切除肝细胞癌Lenvatinib治疗留置率的影响。

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13904

Ryosuke Wakamatsu, Mizuki Nakayama, Ayaka Wakamatsu, Yuki Yamashita, Hiroo Suto, Miki Katsuragawa, Akio Shibanami, Kazuya Hiura

{"title":"Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma.","authors":"Ryosuke Wakamatsu, Mizuki Nakayama, Ayaka Wakamatsu, Yuki Yamashita, Hiroo Suto, Miki Katsuragawa, Akio Shibanami, Kazuya Hiura","doi":"10.21873/invivo.13904","DOIUrl":"10.21873/invivo.13904","url":null,"abstract":"Background/aim: Several studies have reported the association between lenvatinib (LEN) treatment and nutritional indices. However, no study has used multiple nutritional indices or reported their changes during treatment. This study aimed to clarify the association between LEN treatment and nutritional status.Patients and methods: Patients with hepatocellular carcinoma (n=103) treated with LEN were divided into two groups, namely normal and poor nutritional groups, using the Controlling Nutritional Status (CONUT) score, Onodera-Prognostic Nutritional Index (O-PNI), modified Glasgow Prognostic Score (mGPS), and Geriatric Nutritional Risk Index (GNRI). Treatment retention rates were then compared between the two groups. Additionally, changes in nutritional indices from the start of treatment to the end of the observation period or treatment were analyzed to determine their relationship with treatment continuation.Results: Patients with normal nutrition according to the CONUT score, O-PNI, mGPS, and GNRI had a significantly higher rate of treatment retention than those with poor nutrition. Furthermore, both a normal CONUT score and mGPS indicated a lower likelihood of discontinuation due to adverse events. Patients in whom treatment was continued were significantly more likely to maintain or improve their CONUT score.Conclusion: Maintaining or restoring a normal nutritional status is important to ensure continued treatment with LEN. Both the combination of the CONUT score and mGPS at the start of LEN treatment, and the CONUT score during treatment, are useful indicators of nutritional status.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"988-999"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Feasibility of Outpatient Zolbetuximab Administration in Community Cancer Care: A Mixed-methods Analysis. 社区癌症护理中门诊使用唑仑妥昔单抗的安全性和可行性：一项混合方法分析。

IF 1.8 4区医学

In vivo Pub Date : 2025-03-01 DOI: 10.21873/invivo.13900

Erina Yakuwa, Yuko Shoji, Takashi Oizumi, Yuka Kobayashi, Taichi Motoishi, Takuto Katagiri, Shuhei Suzuki

{"title":"Safety and Feasibility of Outpatient Zolbetuximab Administration in Community Cancer Care: A Mixed-methods Analysis.","authors":"Erina Yakuwa, Yuko Shoji, Takashi Oizumi, Yuka Kobayashi, Taichi Motoishi, Takuto Katagiri, Shuhei Suzuki","doi":"10.21873/invivo.13900","DOIUrl":"10.21873/invivo.13900","url":null,"abstract":"Background/aim: Zolbetuximab, a CLAUDIN18.2-targeted antibody, traditionally requires inpatient administration due to potential adverse events. This study evaluated the safety and feasibility of outpatient administration in a community cancer center setting.Patients and methods: Five patients with CLAUDIN18.2-positive advanced gastric cancer received outpatient zolbetuximab between July and November 2024. We implemented a structured protocol incorporating standardized premedication, hospital-pharmacy collaboration, and comprehensive monitoring. Safety, treatment adherence, economic outcomes, and patient experiences were analyzed using mixed methods.Results: No grade 3 or higher adverse events were observed, with mild nausea being the most common toxicity. Treatment adherence was high, with only two patients experiencing non-toxicity-related delays. Outpatient administration reduced costs by approximately 10-15% compared to inpatient administration. Qualitative analysis revealed that while anticipated clinical challenges were effectively managed, practical aspects such as transportation and financial considerations emerged as primary patient concerns. One patient proceeded to conversion surgery, one discontinued due to financial constraints, and three continue treatment.Conclusion: Outpatient zolbetuximab administration proved safe and feasible in a community setting when implemented with appropriate protocols and support systems. This implementation model could serve as a template for delivering complex cancer therapies in resource-limited settings.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"951-960"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0